Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma.
Med
; 5(9): 1038-1040, 2024 Sep 13.
Article
en En
| MEDLINE
| ID: mdl-39276766
ABSTRACT
Immunotherapy has revolutionized the treatment landscape of esophageal squamous cell carcinoma. He et al. present the final results of the randomized phase 3 ESCORT-1st trial, confirming positive survival outcomes when adding the anti-PD1 inhibitor camrelizumab to first-line chemotherapy treatment in Chinese patients with esophageal squamous cell cancer.1.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Esofágicas
/
Anticuerpos Monoclonales Humanizados
/
Carcinoma de Células Escamosas de Esófago
/
Inhibidores de Puntos de Control Inmunológico
Límite:
Humans
Idioma:
En
Revista:
Med
Año:
2024
Tipo del documento:
Article